Sam Jactel

Sam Jactel is the CEO & Founder of Ayble Health. In 2014, he was diagnosed with Ulcerative Colitis. He has experienced first-hand how hard it is to manage these kinds of conditions outside of the clinic and with Ayble, he’s building the solution he wished had existed when he was diagnosed.

Sam’s professional background is multidisciplinary but healthcare centric. Prior to founding Ayble, he led growth strategy and new product innovation at Ginkgo Bioworks, including helping bring the company public and selling employer-focused healthcare services (COVID-19 back-to-work testing), now a $400M P&L. He joined Ginkgo from health-technology venture capital at Flare Capital Partners, where he invested in tech-driven businesses tackling issues in real-world evidence, provider burnout, suicide prevention and women’s health. As a strategy consultant at Accenture, he advised Fortune 500 healthcare clients on new product launches, including market access, mergers & acquisitions and digital therapeutic modalities, both in the US and the EU.

Prior to Accenture, Sam led clinical research initiatives at Emory School of Medicine and Children’s Healthcare of Atlanta, focused on finding innovative ways to treat childhood GI conditions, cancers and infectious diseases.

Sam is a published author of 8 peer reviewed publications, two textbooks, and currently serves on the review board for the Department of Defense’s Congressionally Directed Medical Research Program for IBD, helping evaluate scientific research grants and allocate close to $500M to find a cure for Crohn’s Disease and Ulcerative Colitis.

Sam earned a B.S. in Biology and Philosophy from Duke University and an MBA from the Kellogg School of Management at Northwestern, where he was a Zell Fellow. He’s an avid (and award-winning) travel, landscape and portrait photographer in his spare time.